Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]

  • Awaiting development
  • GID-TA11659
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Trastuzumab deruxtecan with chemotherapy within its marketing authorisation for treating HER2+ solid tumours